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unting for the “Sweet Spot”
n P2Y12 Receptor Blockade*
aniel I. Simon, MD, Sahil A. Parikh, MD
leveland, Ohio
he addition of the P2Y12 antagonist clopidogrel to aspirin
educes ischemic events in unstable angina/non–ST-
egment elevation myocardial infarction treated with med-
cal therapy, percutaneous coronary intervention (PCI), or
oronary artery bypass grafting (1), in ST-segment elevation
yocardial infarction (STEMI) treated with thrombolytic
herapy (2), and in elective PCI (3). Dual antiplatelet
herapy also reduces major adverse cardiovascular events and
tent thrombosis after PCI compared with aspirin alone or
he combination of aspirin and warfarin (4). However, there
re significant limitations of clopidogrel therapy. Clopi-
ogrel is a pro-drug with a slow onset of action, requiring
onversion to an active thiol metabolite by the hepatic
ytochrome P450 (CYP450) system (5). The degree of
See page 1438
latelet inhibition induced by clopidogrel is highly variable
mong individuals with “hyporesponsiveness” occurring in
p to 30% of individuals receiving a 300-mg loading
ose (6). Persistent high platelet reactivity despite clopi-
ogrel therapy is associated with adverse clinical outcomes
n a variety of clinical settings (7,8). Multiple cellular,
linical, and genetic factors likely contribute to clopidogrel
onresponsiveness (9). Increasing clopidogrel dose (10) or
YP450 activity enhances the platelet inhibitory response
f clopidogrel by increasing the concentration of the active
etabolite (5). Conditions or “risk factors” associated inde-
endently with clopidogrel nonresponsiveness include con-
estive heart failure, body weight (100 kg), myocardial
nfarction presentation, and diabetes mellitus (8). Genetic
olymorphisms, particularly of genes responsible for the
etabolism of clopidogrel, such as the *2 allele of CYP450
C19, result in loss of function leading to reduced conver-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University Hospitals Harrington-McLaughlin Heart & Vascular Insti-
ute, Case Western Reserve University School of Medicine, Cleveland, Ohio. Dr.
imon has received consulting and lecture fees from Daichi Sankyo, Cordis/Johnsonc
Johnson, Eli Lilly, The Medicines Company, and Sanofi-Aventis, and serves on
dvisory boards for Cordis/Johnson & Johnson and Medtronic Vascular.ion of clopidogrel to its active metabolite and are associated
ith a higher rate of adverse cardiovascular events in
atients presenting with acute coronary syndromes (11). An
dditional limitation of clopidogrel involves drug–drug
nteractions. The use of drugs that inhibit the activity of
YP2C19, including several of the proton pump inhibitors
PPIs), could result in reduced drug levels of the active
etabolite and a possible reduction in clinical efficacy. A
etrospective cohort study of more than 16,700 patients who
eceived clopidogrel post-stenting reported an increase in
he 1-year risk of cardiovascular events in patients taking a
PI on top of clopidogrel as compared with patients not
aking a PPI (hazard ratio [HR]: 1.51, 95% confidence
nterval [CI]: 1.39 to 1.64; p  0.0001) (12).
Next generation P2Y12 receptor antagonists such as
rasugrel, ticagrelor, and elinogrel have enhanced potency
with the potential for 80% inhibition of platelet aggre-
ation), more rapid onset (seconds to 60 min), and
arkedly reduced response variability (13,14). They are
urrently being evaluated in phase II/III clinical trials.
etermining the appropriate “sweet spot” of platelet inhib-
tory response—namely, the dose that achieves a concentra-
ion of drug that optimizes the balance of efficacy and
afety—remains a major goal and focus of these trials. In the
990s, trials of reversible, competitive antagonists of glyco-
rotein IIb/IIIa showed that 80% inhibition of adenosine
iphosphate-induced platelet aggregation represented the
weet spot for this class of drugs (15). P2Y12 antagonists are
f several pharmacologic subtypes: irreversible for clopi-
ogrel and prasugrel; reversible and noncompetitive for
icagrelor; while elinogrel and cangrelor are reversible,
ompetitive antagonists of P2Y12. Prasugrel has demon-
trated superior clinical efficacy to clopidogrel (300-mg
oading dose, 75-mg maintenance dose) therapy; however,
nhanced efficacy was accompanied by a significant excess of
ajor and minor bleeding (13). Tantalizing evidence from a
eries of small clinical trials suggests that increasing the
oading dose of clopidogrel to 600 mg reduces ischemic
vents in-hospital and up to 30 days without increasing the
ate of bleeding (16,17). Pre-clinical studies have shown
hat reversible P2Y12 antagonists, both noncompetitive and
ompetitive, have an improved therapeutic index versus
lopidogrel (18). It is not yet known whether the sweet spot
iffers for the 3 pharmacologic subtypes and whether these
gents will provide improved clinical efficacy with less
leeding in patients.
In this issue of the Journal, the HORIZONS-AMI
Harmonizing Outcomes With Revascularization and
tents in Acute Myocardial Infarction) study investigators
xplored the potential benefits of a 600-mg loading dose of
lopidogrel compared with 300 mg in the clinical setting of
rimary PCI for STEMI (19). The main HORIZONS-AMI
rial was designed to determine the net clinical benefit of
ivalirudin compared with unfractionated heparin plus gly-
oprotein IIb/IIIa therapy (20). Randomization was strati-
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The “Sweet Spot” in Antiplatelet Therapy October 6, 2009:1447–9ed by clopidogrel loading dose. Patients in the 600-mg
n  2,158) group compared with the 300-mg (n  1,153)
lopidogrel loading dose group had significantly lower rates
f death, reinfarction, and stent thrombosis. By multivari-
ble analysis, a 600-mg loading dose was an independent
redictor of lower rates of 30-day major adverse cardiovas-
ular events (HR: 0.72, 95% CI: 0.53 to 0.98, p  0.04).
his finding suggests that the favorable pharmacodynamic
roperties of increasing clopidogrel dose from 300 to 600
g—namely, greater inhibition with faster onset of action and
educed rate of nonresponsiveness/hyporesponsiveness—are
ssociated with improved clinical outcomes.
The results of the HORIZONS-AMI trial need to be
onsidered in the context of recent lessons from the
TEMI subanalysis (21) of the TRITON–TIMI 38
Trial to Assess Improvement in Therapeutic Outcomes
y Optimizing Platelet Inhibition with Prasugrel–
hrombolysis In Myocardial Infarction 38) trial compar-
ng prasugrel (60-mg loading dose, 10-mg maintenance
ose) with clopidogrel (300-mg loading dose, 75-mg
aintenance dose) in patients undergoing PCI for acute
oronary syndromes (22). Treatment with prasugrel sig-
ificantly reduced the rate of adverse cardiovascular
vents compared with treatment with clopidogrel (HR:
.68, 95% CI: 0.54 to 0.87; p  0.0017). However, when
nly patients undergoing primary PCI were considered,
he superiority of prasugrel over clopidogrel was less
vident (HR: 0.80, 95% CI: 0.60 to 1.08; p  0.144).
The results of the HORIZONS-AMI and TRITON–
IMI 38 STEMI substudies might lead the reader to ask
highly relevant clinical question: is clopidogrel 600 mg
s effective or nearly as effective as prasugrel 60 mg? The
efinitive answer to this question will require a random-
zed comparison between these agents. Although primary
nd point definitions differed in the 2 substudies, it is
seful to evaluate the absolute and relative risk reductions
ith respect to the common 300-mg clopidogrel loading
ose groups in each trial (Table 1). Importantly, assign-
ent to clopidogrel 600/75 mg compared with 300/75
R and AR Reductions in theORIZONS-AMI and TRITON–TIMI 38 TrialsTable 1 HR A Reductions in theHORIZONS-AMI and TRITON–TIMI 38 Trials
Clopidogrel
300/75 mg
Clopidogrel
600/75 mg HR AR
HORIZONS-AMI* 7.0% 4.3% 0.72 2.7%
Clopidogrel
300/75 mg
Prasugrel
60/10 mg
TRITON–TIMI 38†
All STEMI 9.5% 6.5% 0.68 3.0%
Primary PCI 8.2% 6.6% 0.80 1.6%
HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial
nfarction) trial end point: all death, stroke, reinfarction, and unplanned revascularization for
schemia; †TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing
latelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) study end point:
ardiovascular death, nonfatal myocardial infarction, nonfatal stroke.h
AR  absolute risk; HR  hazard ratio; PCI  percutaneous coronary intervention; STEMI 
T-segment elevation myocardial infarction.g in the HORIZONS-AMI trial was nonrandomized
nd left to the discretion of the physician, raising the
ossibility that significant measured and unmeasured
ariables may have contributed to the apparent clinical
enefits of clopidogrel 600/75 mg despite attempts to
inimize confounding by performing propensity-
atched analysis.
The results of the HORIZONS-AMI substudy are
rovocative, as the 600-mg loading dose may have been
ore effective than the 300-mg loading dose for multiple
easons, as diagramed in Figure 1. First, since thrombi
re dynamic, and P2Y12 signaling is known to be involved
n platelet adhesion and subsequent activation as well as
n thrombus growth, clopidogrel could have provided
enefit by stopping platelet recruitment and favoring
ndogenous mechanisms (e.g., endogenous fibrinolysis)
o achieve dissolution of the occlusive thrombus. Alter-
atively, since persistent signaling by adenosine diphos-
hate acting on P2Y12 is required to maintain glyco-
rotein IIb/IIIa in the activated state within a platelet
ggregate (23), the expected doubling of the concentra-
ion of the active metabolite by the 600-mg dose could
ave directly induced reversal of existing thrombi. Future
tudies are required to determine whether the concentra-
ions of active metabolites of the thienopyridines present
fter the 600-mg dose of clopidogrel, which are more
bundant and form earlier after the 60-mg dose of
rasugrel, are sufficient to achieve thrombus reversal and
hether the new reversible P2Y12 antagonists are even
ore effective dethrombotic agents.
cknowledgment
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Figure 1 Potential Role of P2Y12 Antagonism
in Reversing Platelet Aggregation and Thrombosis
P2Y12 signaling after platelet stimulation by thrombin or collagen promotes
activation of the receptor function of glycoprotein (GP) IIb/IIIa, fibrinogen bind-
ing, and platelet aggregation. Since continued P2Y12 signaling is required to
maintain the activation state of GP IIb/IIIa and aggregate stability, addition of
P2Y12 antagonists to aggregated platelets in a thrombus is capable of revers-
ing thrombosis. ADP  adenosine diphosphate; vWf  von Willebrand factor.is critical review of the manuscript.
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